Trautmann M, Zhuang D, , DURATION-1 Study Group, et al (2008) Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372: 1240-1250.
19. Okerson T, Yan P, Stonehouse A, Brodows R, Bhole D (2008) Exenatide improved systolic blood pressure compared to insulin or placebo in patients with type 2 diabetes. Diabetologia
51: S350.
20. Bergenstal R, Kim T, Yan P, Darsow T, Walsh B, Okerson T, et al (2009) Exenatide once
weekly improved cardiometabolic risk factors in subjects with type 2 diabetes during one year of treatment. Diabetes 58: A43.
21. Bhushan R, Elkind-Hirsch KE, Bhushan M, Butler WJ, Duncan K, Marrioneaux O (2009) Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with Exenatide in a clinical practice setting. Diabetes TechnolTher 11 (6): 353-359.
22. Kothare PA, Linnebjerg H, Isaka Y, Uenaka K, Yamamura A, Yeo KP, et al (2008) Pharmacokinetics, pharmacodynamics, tolerability, and safety of Exenatide in Japanese patients with type 2 diabetes mellitus. J ClinPharmacol 48: 1389-1399.
23. Linnebjerg H, Kothare P, Park S, Mace K, Mitchell M (2009) The effect of Exenatide on lisinopril pharmacodynamics and pharmacokinetics in patients with hypertension. Int J ClinPharmacolTher 47 (11): 651-658.
24. Menéndez Torre E, Lafita Tejedor J, Artola Menéndez S, Millán Núñez-Cortés J, Alonso García Á, Puig Domingo M, et al (2010) Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2. Av Diabetolo 26: 331-338.
25. Svec F (2010) Incretin physiology and its role in type 2 diabetes mellitus. J Am Osteopath Assoc 110 (7 Suppl 7): eS20-24.
26. Sudhakaran C, Fathima M, Anjana RM, Unnikrishnan RI, Mohan V (2010) Effectiveness of Exenatide in Asian Indians in a clinical care setting. Diabetes TechnolTher 12 (8): 613-618.
27. Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K, et al (2010) Once weekly Exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 375 (9733): 2234-2243.
28. Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, et al; DURATION-2 Study Group (2010) Efficacy and safety of Exenatide once weekly versus sitagliptin or
pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a
randomised trial. Lancet 376 (9739): 431-439.
29. Blevins T, Han J, Nicewarner D, Chen S, Oliveira JH, Aronoff S (2010) Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes. Postgrad Med 122 (3): 118-128.
30. Natarajan B, Edavalath M, Davies J, Jenkins L, Marshall-Richards N, Evans D, et al (2010) Clinical experience with Exenatide in a routine secondary care diabetes clinic. Prim Care Diabetes 4 (1): 57-60.
31. Yoon NM, Cavaghan MK, Brunelle RL, Roach P (2009) Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. ClinTher 31 (7): 1511-1523.
32. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, et al; DURATION¬1 Study Group (2008) Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372 (9645): 1240-1250.
33. Forti A, Garcia EG, Yu MB, Jimenez MC, Brodows RG, Oliveira JH (2008) Efficacy and safety of Exenatide administered before the two largest daily meals of Latin American patients with type 2 diabetes. Curr Med Res Opin 24 (9): 2437-2447.
34. Nyström T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahrén B, et al (2004) Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J PhysiolEndocrinolMetab 287: E1209-E1215.
35. Thrainsdottir I, Malmberg K, Olsson A, Gutniak M, Rydén L (2004) Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. DiabVasc Dis Res 1: 40-43.
36. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP (2006) Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 12: 694-699.
37. Bunck MC, Diamant M, Eliasson B, Cornér A, Shaginian RM, Heine RJ, et al (2010) Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care 33 (8): 1734-1737.
38. Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, et al (2010) Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients With Type 2 Diabetes: A Randomized, Controlled Trial. Ann Intern Med 154 (2): 1-12.
39. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, et al (2003) Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 88 (7): 3082-3089.
40. Arnolds S, Dellweg S, Clair J, Dain MP, Nauck MA, Rave K, et al (2010) Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care 33 (7): 1509-1515.
41. Yoon NM, Cavaghan MK, Brunelle RL, Roach P (2009) Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther 31 (7): 1511-1523.
42. Sheffield CA, Kane MP, Busch RS, Bakst G, Abelseth JM, Hamilton RA (2008) Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. Endocr Pract 14 (3): 285-292.
43. Nayak UA, Govindan J, Baskar V, Kalupahana D, Singh BM (2010) Exenatide therapy in insulin-treated type 2 diabetes and obesity. QJM 103 (9): 687-694.